{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:23Z","timestamp":1791932363551,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.027","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:10:41Z","timestamp":1568999441000},"page":"6696-6706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine"],"prefix":"10.1016","volume":"37","author":[{"given":"Ozan S.","family":"Kumru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraia","family":"Saleh-Birdjandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena R.","family":"Antunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"van den Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey S.","family":"Diemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Caposio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.027_b0005","unstructured":"Davison AJ, Bhella D. Comparative genome and virion structure. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, et al., editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge; 2007."},{"key":"10.1016\/j.vaccine.2019.09.027_b0010","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1099\/vir.0.79888-0","article-title":"Genetic content of wild-type human cytomegalovirus","volume":"85","author":"Dolan","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0015","doi-asserted-by":"crossref","first-page":"10960","DOI":"10.1128\/JVI.78.20.10960-10966.2004","article-title":"Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome","volume":"78","author":"Varnum","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.09.027_b0025","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.027_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210252","article-title":"Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge","volume":"14","author":"Hansen","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.027_b0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"issue":"501","key":"10.1016\/j.vaccine.2019.09.027_b0045","doi-asserted-by":"crossref","first-page":"eaaw2607","DOI":"10.1126\/scitranslmed.aaw2607","article-title":"A live-attenuated RhCMV\/SIV vaccine shows long-term efficacy against heterologous SIV challenge","volume":"11","author":"Hansen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.09.027_b0050","first-page":"In press","article-title":"Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity","author":"Marshall","year":"2019","journal-title":"Sci Transl Med"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2019.09.027_b0055","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/cid\/cit587","article-title":"Cytomegalovirus vaccines","volume":"57","author":"McVoy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.027_b0060","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2019.09.027_b0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.biologicals.2009.08.004","article-title":"Stability evaluation of vaccines: WHO approach","volume":"37","author":"Knezevic","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.09.027_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.09.027_b0075","first-page":"1","article-title":"Formulation, stability, and delivery of live attenuated vaccines for human use","volume":"16","author":"Burke","year":"1999","journal-title":"Crit Rev Ther Drug"},{"key":"10.1016\/j.vaccine.2019.09.027_b0080","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1016\/j.vaccine.2011.07.054","article-title":"Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines","volume":"29","author":"Wiggan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0085","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1016\/j.vaccine.2007.02.052","article-title":"Freezing temperatures in the vaccine cold chain: a systematic literature review","volume":"25","author":"Matthias","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0090","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2017.04.086","article-title":"Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate","volume":"36","author":"Patel","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0095","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.xphs.2018.01.027","article-title":"Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the nanopatch (TM) microprojection array","volume":"107","author":"Wan","year":"2018","journal-title":"J Pharm Sci-Us"},{"key":"10.1016\/j.vaccine.2019.09.027_b0100","doi-asserted-by":"crossref","first-page":"14976","DOI":"10.1073\/pnas.2136652100","article-title":"Coding potential of laboratory and clinical strains of human cytomegalovirus","volume":"100","author":"Murphy","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.09.027_b0105","doi-asserted-by":"crossref","unstructured":"Caposio P, van den Worm S, Crawford L, Perez W, Kreklywich C, Gilbride RM, et al. Characterization of a live-attenuated HCMV-based vaccine platform. Manuscript submitted for publication; 2019.","DOI":"10.1038\/s41598-019-55508-w"},{"key":"10.1016\/j.vaccine.2019.09.027_b0110","doi-asserted-by":"crossref","first-page":"14506","DOI":"10.1073\/pnas.97.26.14506","article-title":"UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells","volume":"97","author":"Bresnahan","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.09.027_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041936","article-title":"A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"Keefer","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.027_b0120","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0125","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.02676-05","article-title":"Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication","volume":"80","author":"Cantrell","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0130","unstructured":"https:\/\/www.fda.gov\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm093833.htm. Vaccines Licensed for Use in the United States, Date accessed: 2\/14\/2019. U.S. Food and Drug Administration; 2019."},{"key":"10.1016\/j.vaccine.2019.09.027_b0135","unstructured":"Fu T-M, Wang D, Medi MB. European Patent Specification: EP3251700B1 A conditional replicating cytomegalovirus as a vaccine for CMV. 2019."},{"key":"10.1016\/j.vaccine.2019.09.027_b0140","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jps.24211","article-title":"Characterization of an oncolytic herpes simplex virus drug candidate","volume":"104","author":"Kumru","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2019.09.027_b0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye","volume":"36","author":"Rodrigues","year":"2018","journal-title":"Pharm Res."},{"key":"10.1016\/j.vaccine.2019.09.027_b0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/COH.0000000000000524","article-title":"Human cytomegalovirus-vectored vaccines against HIV","volume":"14","author":"Abad-Fernandez","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2019.09.027_b0160","doi-asserted-by":"crossref","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.09.027_b0165","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E","volume":"351","author":"Hansen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.09.027_b0170","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.2147\/OTT.S133699","article-title":"A practical guide to the handling and administration of talimogene laherparepvec in Europe","volume":"10","author":"Harrington","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.vaccine.2019.09.027_b0175","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/jb.91.1.221-226.1966","article-title":"Thermoinactivation of human cytomegalovirus","volume":"91","author":"Vonka","year":"1966","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0180","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","article-title":"Freeze-drying of live virus vaccines: a review","volume":"33","author":"Hansen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0185","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0140-7007(00)00027-X","article-title":"Cellular cryobiology: thermodynamic and mechanical effects","volume":"24","author":"Wolfe","year":"2001","journal-title":"Int J Refrig"},{"key":"10.1016\/j.vaccine.2019.09.027_b0190","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2019.09.027_b0195","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.xphs.2018.07.010","article-title":"Physical characterization and stabilization of a lentiviral vector against adsorption and Freeze-Thaw","volume":"107","author":"Kumru","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2019.09.027_b0200","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jps.20496","article-title":"Effect of pH and ionic strength on the physical stability of adenovirus type 5","volume":"95","author":"Rexroad","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2019.09.027_b0205","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1128\/jvi.13.5.1030-1036.1974","article-title":"Effect of ionic strength on the binding of Sindbis virus to chick cells","volume":"13","author":"Pierce","year":"1974","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01317899","article-title":"Adenovirus aggregation and preservation in extracellular environment","volume":"59","author":"Galdiero","year":"1979","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.09.027_b0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-8518-5-4","article-title":"Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka\/Merck live varicella vaccine","volume":"5","author":"Liska","year":"2007","journal-title":"J Immune Based Ther Vaccines"},{"key":"10.1016\/j.vaccine.2019.09.027_b0220","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.pep.2004.11.016","article-title":"Expression and characterization of a low molecular weight recombinant human gelatin: development of a substitute for animal-derived gelatin with superior features","volume":"40","author":"Olsen","year":"2005","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2019.09.027_b0225","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1016\/j.vaccine.2018.01.089","article-title":"A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX(R)","volume":"37","author":"Reisinger","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0235","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1542\/peds.2006-2283","article-title":"Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live)","volume":"119","author":"Bernstein","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.09.027_b0240","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.vaccine.2016.11.097","article-title":"The origins of the vaccine cold chain and a glimpse of the future","volume":"35","author":"Lloyd","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.027_b0245","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1586\/14760584.2014.923761","article-title":"Tools and approaches to ensure quality of vaccines throughout the cold chain","volume":"13","author":"Kartoglu","year":"2014","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:36:39Z","timestamp":1759401399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":48,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312277"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stabilization and formulation of a recombinant Human Cytomegalovirus vector for use as a candidate HIV-1 vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}